Glioma Subclassifications and Their Clinical Significance

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

(2016) Felix Behling et al.   Diagnostic Pathology

Successful Treatment of a ProgressiveBRAFV600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy

(2016) Eudocia Q. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal evolution of glioblastoma under therapy

(2016) Jiguang Wang et al.   NATURE GENETICS

Glioblastoma vaccine therapy disappointment in Phase III trial

(2016) Hemi Malkki   Nature Reviews Neurology

HG-81NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION

(2016) Gary Kohanbash et al.   NEURO-ONCOLOGY

Biology and management of ependymomas

(2016) Jing Wu et al.   NEURO-ONCOLOGY

Pediatric high-grade glioma: biologically and clinically in need of new thinking

(2016) Chris Jones et al.   NEURO-ONCOLOGY

Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma

(2016) Nozomi Matsumura et al.   NEUROPATHOLOGY

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

(2016) Hideyuki Arita et al.   Acta Neuropathologica Communications

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

BRAF VE1 Immunoreactivity Patterns in Epithelioid Glioblastomas Positive for BRAF V600E Mutation

(2015) Bette K. Kleinschmidt-DeMasters et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas-Same Entity or First Cousins?

(2015) Sanda Alexandrescu et al.   BRAIN PATHOLOGY

Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma

(2015) Ji Eun Oh et al.   BRAIN PATHOLOGY

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

(2015) Kristian W. Pajtler et al.   CANCER CELL

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

(2015) Thomas Sandmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of neuropathology in the management of patients with diffuse low grade glioma

(2015) Daniel P. Cahill et al.   JOURNAL OF NEURO-ONCOLOGY

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

SomaticPOLEmutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis

(2015) E. Zeynep Erson-Omay et al.   NEURO-ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib

(2015) Dolly Aguilera et al.   PEDIATRIC BLOOD & CANCER

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH

(2015) K Oizel et al.   Cell Death & Disease

Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation

(2015) Yafei Hou et al.   Journal for ImmunoTherapy of Cancer

DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status

(2015) Adam Cohen et al.   Acta Neuropathologica Communications

Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications

(2014) Pawel Buczkowicz et al.   ACTA NEUROPATHOLOGICA

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

(2014) Giles W Robinson et al.   BMC CANCER

Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up

(2014) Cristiane M. Ida et al.   BRAIN PATHOLOGY

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

(2014) H. Wakimoto et al.   CLINICAL CANCER RESEARCH

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent

(2014) Francesca del Bufalo et al.   Journal of Translational Medicine

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

(2014) S. C. Mack et al.   NATURE

C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma

(2014) Matthew Parker et al.   NATURE

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pilomyxoid astrocytoma treated successfully with vemurafenib

(2014) Mary Skrypek et al.   PEDIATRIC BLOOD & CANCER

MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma

(2014) B. J. Gill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups

(2014) Kirti Gupta et al.   Acta Neuropathologica Communications

Brain stem cells as the cell of origin in glioma

(2014) Aram S Modrek   World Journal of Stem Cells

Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation

(2013) Bette Kay Kleinschmidt-DeMasters et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma

(2013) Krishna P.L. Bhat et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate

(2013) Ovidiu C. Andronesi et al.   JOURNAL OF CLINICAL INVESTIGATION

Brainstem Ganglioglioma Successfully Treated With Vemurafenib

(2013) Sarah Rush et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

(2013) Hairui Sun et al.   JOURNAL OF NEURO-ONCOLOGY

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

(2013) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma

(2013) A. Broniscer et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

(2012) Dong-Anh Khuong-Quang et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

(2012) H. Yang et al.   CLINICAL CANCER RESEARCH

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance

(2012) T. E. Taylor et al.   CURRENT CANCER DRUG TARGETS

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma

(2011) Hendrik Witt et al.   CANCER CELL

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

(2011) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

(2011) Dora Dias-Santagata et al.   PLoS One

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

(2010) Joon H. Uhm et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses†

(2010) Artemis P. Vogazianou et al.   NEURO-ONCOLOGY

Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience

(2010) T. S. Armstrong et al.   NEURO-ONCOLOGY

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

(2010) Margaret J. Dougherty et al.   NEURO-ONCOLOGY

Ependymoma: lessons from the past, prospects for the future

(2009) Eric Bouffet et al.   CHILDS NERVOUS SYSTEM

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity

(2009) Seunggu J. Han et al.   JOURNAL OF NEURO-ONCOLOGY

Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study

(2009) Thomas E Merchant et al.   LANCET ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Giant cell glioblastoma: A glioblastoma subtype with distinct epidemiology and superior prognosis

(2009) Kevin R. Kozak et al.   NEURO-ONCOLOGY

Metabolic Enzymes as Oncogenes or Tumor Suppressors

(2009) Craig B. Thompson   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases

(2008) Addisalem T. Makuria et al.   JOURNAL OF NEURO-ONCOLOGY

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome

(2008) Kevin R. Kozak et al.   NEURO-ONCOLOGY